Myeloid somatic mutation panel testing in myeloproliferative neoplasms

David M. Ross, Candice Thomson, Nada Hamad, Steven W. Lane, Kate Manos, Andrew P. Grigg, Belinda Guo, Wendy N. Erber, Ashleigh Scott, Nick Viiala, Lynette Chee, Maya Latimer, Courtney Tate, Carolyn Grove, Andrew C. Perkins, Piers Blombery

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)


Myeloproliferative neoplasms are characterised by somatic mutations in pathways that regulate cell proliferation, epigenetic modifications, RNA splicing or DNA repair. Assessment of the mutational profile assists diagnosis and classification, but also aids assessment of prognosis, and may guide the use of emerging targeted therapies. The most practical way to provide information on numerous genetic variants is by using massively parallel sequencing, commonly in the form of disease specific next generation sequencing (NGS) panels. This review summarises the diagnostic and prognostic value of somatic mutation testing in Philadelphia-negative myeloproliferative neoplasms: polycythaemia vera, essential thrombocythaemia, primary myelofibrosis, chronic neutrophilic leukaemia, systemic mastocytosis, and chronic eosinophilic leukaemia. NGS panel testing is increasing in routine practice and promises to improve the accuracy and efficiency of pathological diagnosis and prognosis.

Original languageEnglish
Pages (from-to)339-348
Number of pages10
Issue number3
Early online date3 Mar 2021
Publication statusPublished - Apr 2021


Dive into the research topics of 'Myeloid somatic mutation panel testing in myeloproliferative neoplasms'. Together they form a unique fingerprint.

Cite this